title: Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction.
abstract: Doxorubicin (DOX) is a widely prescribed antineoplastic and although the precise mechanism(s) have yet to be identified, DOX-induced oxidative stress to mitochondrial membranes is implicated in the pathogenic process. Previous attempts to protect against DOX-induced cardiotoxicity with alpha-tocopherol (vitamin E) have met with limited success, possibly as a result of inadequate delivery to relevant subcellular targets such as mitochondrial membranes. The present investigation was designed to assess whether enrichment of cardiac membranes with alpha-ocopherol is sufficient to protect against DOX-induced mitochondrial cardiotoxicity. Adult male Sprague-Dawley rats received seven weekly subcutaneous injections of 2 mg/kg DOX and fed either standard diet or diet supplemented with alpha-tocopherol succinate. Treatment with a cumulative dose of 14 mg/kg DOX caused mitochondrial cardiomyopathy as evidenced by histology, accumulation of oxidized cardiac proteins, and a significant decrease in mitochondrial calcium loading capacity. Maintaining rats on the alpha-tocopherol supplemented diet resulted in a significant (two- to four-fold) enrichment of cardiac mitochondrial membranes with alpha-tocopherol and diminished the content of oxidized cardiac proteins associated with DOX treatment. However, dietary alpha-tocopherol succinate failed to protect against mitochondrial dysfunction and cardiac histopathology. From this we conclude that although dietary vitamin E supplementation enriches cardiac mitochondrial membranes with alpha-tocopherol, either (1) this tocopherol enrichment is not sufficient to protect cardiac mitochondrial membranes from DOX toxicity or (2) oxidative stress alone is not responsible for the persistent mitochondrial cardiomyopathy caused by long-term DOX therapy.
authors.affiliation: Department of Biochemistry and Molecular Biology, University of Minnesota Medical School, Duluth, MN 55812, USA. jberthi1@d.umn.edu
authors.forename: J M
authors.initials: JM
authors.lastname: Berthiaume
authors.forename: P J
authors.initials: PJ
authors.lastname: Oliveira
authors.forename: M W
authors.initials: MW
authors.lastname: Fariss
authors.forename: K B
authors.initials: KB
authors.lastname: Wallace
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D001835:Body Weight / Q000187:drug effects; D002118:Calcium / Q000378:metabolism; D004032:Diet; D004317:Doxorubicin / Q000037:antagonists & inhibitors* / Q000633:toxicity*; D006331:Heart Diseases / Q000139:chemically induced / Q000473:pathology; D007202:Indicators and Reagents; D008929:Mitochondria, Heart / Q000187:drug effects* / Q000378:metabolism; D009124:Muscle Proteins / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D009929:Organ Size / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects*; D010101:Oxygen Consumption / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D014810:Vitamin E / Q000494:pharmacology*; D014815:Vitamins / Q000494:pharmacology*
chemical_list: D000903:Antibiotics, Antineoplastic; D007202:Indicators and Reagents; D009124:Muscle Proteins; D014815:Vitamins; D014810:Vitamin E; D004317:Doxorubicin; D002118:Calcium